@article{Rudan_I-2025_211429,
title = {BNT162b2 COVID-19 vaccination uptake, safety, effectiveness, and waning in children and young people aged 5–11 years in Scotland},
author = {Rudan, I. and Kerr, S. and Sullivan, C. and Jeffrey, K. and Grange, Z. and Fenton, L. and Kurdi, A. and Shi, T. and Cullen, L. and Simpson, C. and Katikireddi, S. and Ritchie, L. and Robertson, C. and Sheikh, A.},
month = {aug},
year = {2025},
abstract = {Background Few large-scale population studies have examined both safety and vaccine effectiveness (VE) specifically for 5–11-year-olds during the Omicron-dominant period in a setting with low vaccine uptake. The BNT162b2 (Pfizer-BioNTech) vaccine, administered in two doses, has shown strong efficacy against symptomatic and severe COVID-19 in clinical trials involving children and young people (CYP). Accordingly, we examined the uptake, real-world safety, VE, and waning of BNT162b2 VE against symptomatic COVID-19 among children aged 5–11 years in Scotland.},
volume = {15},
journal = {Journal of Global Health},
publisher = {International Society of Global Health},
url = {https://doi.org/10.7189/jogh.15.04250},
}
